Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 28Lymphoma, Large B-Cell, Diffuse 21Lymphoma 16Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Immunoblastic Lymphadenopathy 4Recurrence 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Primary Effusion 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Waldenstrom Macroglobulinemia 2Plasmablastic Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, T-Cell 2Hematologic Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Etoposide 2prednylidene 1emvododstat 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Vorinostat 1Vincristine 1Rituximab 1Raltegravir Potassium 1Prednisone 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Immunohistochemistry 1Genes 1Gene Expression Profiling 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HIV Infections × Prednisone × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡